Nestlé takes over biopharmaceutic Aimmune Therapeutics. That company is developing remedies against food allergies. The deal gives Aimmune a value of about 2.6 billion dollars. Aimmune has developed Palforzia, a treatment for food allergy. Which would help reduce the severity and frequency of children’s allergic reactions to peanuts. it has been approved by the US Drug Authority FDA. “Together with Aimmune, we will be able to offer a wide range of solutions that can change the lives of people with food allergies around the world,” says Greg Behar of Nestlé Health Science. According to Nestlé, up to 240 million people worldwide suffer from food allergy, the most common of which is a peanut allergy. Nestlé already had a stake of more than 25 percent in the Aimmune listed on the Nasdaq. The gigantic food business offers USD 34.5 per share of Animmune, more than USD 20 above the last closing rate. The takeover is expected to be completed by the end of this year.
